Introduction

Coronavirus disease 2019 (COVID-19), caused by a type of coronavirus known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has emerged as a public health crisis. Till mid-June 2020, the most affected countries like USA, Brazil, Russia, India, UK, Spain and Italy have reported more the 50% of 7.5 million COVID-19 cases. The overall mortality due to COVID-19 is reported close to half of million people, making it the biggest public health crisis of current era [1]. Initially thought to be primarily a disease affecting lung and causing pneumonia, now found to be involving various tissues and systems including causing thromboembolism, stroke and renal failure.

Though, coronavirus infection is affecting all age groups, sex, race, ethnicity and continents, few groups or people are more susceptible to getting infected with coronavirus and few of them have higher chance of adverse disease progression including death. The risk factors for COVID-19 are old age people having co-morbidities including diabetes, hypertension, cancer, respiratory diseases, cardio-cerebrovascular diseases and renal diseases. Patients with these co-morbidities are found to be at a higher risk of severe COVID-19 progression including deaths [2].

Tobacco smoking is a known major risk factor associated with many of these disease conditions, especially related with respiratory system [3]. Tobacco consumption, specially smoking and waterpipe, affect the lung capacity which may lead to difficulty in breathing added by long term harmful effect of cardiovascular and respiratory system leading to elevated risk of various kind of infectious diseases [4]. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, which primarily affects the lungs, is found to be associated with severe events in people who consume tobacco either smokeless or with smoke. Many studies showed that smokers, either current or former, show the severe COVID-19 progression. Yet there is no strong evidence which establishes the link between tobacco smoking and COVID-19. Smoking causes increase in secretory cells of respiratory tract, subsequently increasing ACE-2 expression. Ageing is also associated with a higher expression of ACE-2 gene. This can possibly explain the vulnerability of aged people, smokers and patients with hypertension to coronavirus and also people who consume tobacco, either smokeless or smoke, as a potential vulnerable group for COVID-19.
which establishes the link between tobacco smoking and COVID-19.

Tobacco is being consumed worldwide in various forms which include tobacco chewing, paan masala, bidi, taibur (liquid water), cigarette smoking etc. Thus, people who consume tobacco are also found to be at an increased risk of contracting SARS-CoV-2 infection. The reason behind smoking being a risk factor for COVID-19 can be linked with Angiotensin-converting enzyme II (ACE-2). Expression of ACE-2 gene is increased in people who smoke. ACE-2 is found to be associated with SARS-CoV-2, which uses it as a receptor for cellular entry. Smoking causes an increase in secretory cells of respiratory tract, subsequently increasing ACE-2 expression [5]. Ageing is also associated with a higher expression of ACE-2 gene [4]. This can possibly explain the vulnerability of aged people, smokers and patients with hypertension to coronavirus and person who consume tobacco, either smokeless or smoke, as a potential vulnerable group for COVID-19.

Tobacco smoking makes respiratory system prone to many infections. Consumption of tobacco, either smoke or smokeless, is responsible for destroying the cells of immune system as reported in many studies showing that smokers are more prone to the allergic symptoms (influenza like) and higher deaths recorded in previous Middle East Respiratory Syndrome Coronavirus (MERS-CoV) outbreak among smokers in comparison to non-smokers [4]. Smoking and consuming smokeless tobacco products can possibly correlate with the severities of COVID-19 morbidities, as many evidence based studies highlighted the negative impact of these products on lungs health including COPD (Chronic obstructive Pulmonary Disease), severe degree of pneumonia and cancer, on heart including coronary heart disease, stroke and hypertension [3-6].

Higher rate of severe events are found in people who are infected with coronavirus, and having co-morbidities like hypertension, cancer, diabetes, respiratory problems [2]. Tobacco smoking is associated with higher rate of severe events in Coronavirus disease (COVID-19). In US, around 7162 cases of COVID-19 with complete history of health related data found that 3.6% of cases were current or former smokers and contributes to 6% and 8% cases of hospitalized and Intensive Care Units (ICUs) admission, respectively [7]. Many of the studies conducted in China also reported higher ICU admission rate of patients having history of smoking, either current or former [4].

According to Chinese research study, smokers, either current or former, show the severe COVID-19 progression. In all patients with severe disease progression, every 1 out of 5 was a smoker, 16.9% current and 5.2% former smokers, while only 11.8% current and 1.3% former smokers were found with non-severe COVID-19 symptoms [8]. Many observational studies found that percentage of smokers is 1.4 – 18.5% of hospitalized cases of COVID-19 and severity of COVID-19 is higher among them with an odds ratio of 2.2 [9].

Another research study of China shows that the progression (symptom severity) group had a significantly higher proportion of patients with a history of smoking than the improvement/stabilization group (27.3% vs. 3.0%, χ²=9.291, P =0.018). The progression group was found to receive higher respiratory support in comparison to the other group [10].

Smoking is the biggest cause of lung cancer in developed and developing countries. Patients with lung cancer were found at a higher risk of coronavirus transmission among all cancer types with an increased risk of severe events and deaths. Among all the deaths in patients with cancer due to COVID-19, deaths in patient with lung cancer contribute highest [4].

The world is already facing burden of tobacco related diseases and COVID-19 may be the new entry in this. Though there are limited studies available which show the severity of COVID-19 progression and outcome in people with tobacco consumption, and more robust data is needed to establish the relation, but in view of the current pandemic, evidence suggests implementing tobacco control and smoking cessation strategies more strictly to reduce further burden.

References


This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.